

**Table S1.** Differences in demographic and clinical characteristics between participants in the study sample and participants excluded due to missing baseline data.

<b>Variable</b>	<b>Excluded</b>	<b>Included</b>	<b>p-value</b>
	<i>n</i> =1608 (62.08%)	<i>n</i> =982 (37.92%)	
ART regimen category			0.406
Boosted PI <sup>1</sup>	618 (38.43%)	352 (35.85%)	
NNRTI <sup>2</sup>	578 (35.95%)	364 (37.07%)	
INSTI <sup>3</sup>	412 (25.62%)	266 (27.09%)	
Age at ART initiation (years)	35.9 (30.3, 44.0)	35.2 (29.7, 42.9)	0.010
Female sex	202 (12.56%)	80 (8.15%)	<0.001
Transmission mode			<0.001
MSM <sup>4</sup>	1026 (63.81%)	665 (67.72%)	
PWID <sup>5</sup>	170 (10.57%)	129 (13.14%)	
Heterosexual	292 (18.16%)	144 (14.66%)	
NA <sup>6</sup>	120 (7.46%)	44 (4.48%)	
Ethnic/racial group	10.00 (10.00, 10.00)	10.00 (10.00, 10.00)	<0.001
White	1492 (92.79%)	918 (93.48%)	
Black	79 (4.91%)	9 (0.92%)	
Asian	10 (0.62%)	3 (0.31%)	
Middle East/Arab	3 (0.19%)	0 (0.00%)	
NA <sup>6</sup>	24 (1.49%)	52 (5.30%)	
Year of ART initiation	2013 (2011, 2015)	2013 (2011, 2015)	0.176
AIDS before baseline	141 (8.77%)	42 (4.28%)	<0.001
Baseline <sup>7</sup> CD4 (cells/μl)	306 (180, 417)	325 (212, 428)	0.002
Baseline <sup>7</sup> HIV-RNA (log <sub>10</sub> c/ml)	4.50 (3.86, 5.10)	4.50 (3.94, 4.99)	0.769

<sup>1</sup>Protease Inhibitors; <sup>2</sup>Non-Nucleoside Reverse Transcriptase Inhibitors; <sup>3</sup>Integrase Strand Inhibitors; <sup>4</sup>Men having sex with men; <sup>5</sup>People who inject drugs; <sup>6</sup>Non-Available; <sup>7</sup>At ART initiation, available for 1498/1608 (CD4) and 1525/1608 (HIV-RNA).




Figure S1. Flowchart for inclusion/exclusion criteria.